MedPath

GARDASIL 9

GARDASIL 9

Approved
DIN Number

02437058

Drug Class

Human

Market Date

Mar 18, 2015

Company
HC

Merck Canada Inc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02437058
AIG Number0956550001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Schedule D
A
ATC Code
J07BM03 PAPILLOMAVIRUS (HUMAN TYPES 6,11,16,18,31,33,45,52,58)
Product Specifications
Dosage FormSuspension
Route of AdministrationIntramuscular
AHFS Classification80:12.00
Health Canada Classification

ACTIVE INGREDIENTS (9)

RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 11 L1 PROTEINActive
Strength: 40 MCG / 0.5 ML
Monograph: RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 11 L1 PROTEIN
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEINActive
Strength: 60 MCG / 0.5 ML
Monograph: RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEINActive
Strength: 40 MCG / 0.5 ML
Monograph: RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 31 L1 PROTEINActive
Strength: 20 MCG / 0.5 ML
Monograph: RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 31 L1 PROTEIN
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 33 L1 PROTEINActive
Strength: 20 MCG / 0.5 ML
Monograph: RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 33 L1 PROTEIN
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 45 L1 PROTEINActive
Strength: 20 MCG / 0.5 ML
Monograph: RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 45 L1 PROTEIN
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEINActive
Strength: 20 MCG / 0.5 ML
Monograph: RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 58 L1 PROTEINActive
Strength: 20 MCG / 0.5 ML
Monograph: RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 58 L1 PROTEIN
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 6 L1 PROTEINActive
Strength: 30 MCG / 0.5 ML
Monograph: RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 6 L1 PROTEIN

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.